These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30971215)

  • 1. Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM).
    Soler A; Amer G; Leiva A; Ripoll J; Llorente MA; Leiva A; Taltavull JM; Molina R; Llobera J
    BMC Geriatr; 2019 Apr; 19(1):101. PubMed ID: 30971215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.
    Buckley JS; Salpeter SR
    Drugs Aging; 2015 Jun; 32(6):453-67. PubMed ID: 25941104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.
    Grossberg GT; Alva G; Hendrix S; Ellison N; Kane MC; Edwards J
    Alzheimer Dis Assoc Disord; 2018; 32(3):173-178. PubMed ID: 29771687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.
    Raina P; Santaguida P; Ismaila A; Patterson C; Cowan D; Levine M; Booker L; Oremus M
    Ann Intern Med; 2008 Mar; 148(5):379-97. PubMed ID: 18316756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.
    Reeve E; Farrell B; Thompson W; Herrmann N; Sketris I; Magin PJ; Chenoweth L; Gorman M; Quirke L; Bethune G; Hilmer SN
    Med J Aust; 2019 Mar; 210(4):174-179. PubMed ID: 30771226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
    Li Y; Hai S; Zhou Y; Dong BR
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009444. PubMed ID: 25734590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
    Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
    J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
    Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
    J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine for dementia.
    Areosa Sastre A; McShane R; Sherriff F
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003154. PubMed ID: 15495043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Anti-Dementia Drugs in Extremely Severe Alzheimer's Disease: A 12-Week, Multicenter, Randomized, Single-Blind Study.
    Hong YJ; Choi SH; Jeong JH; Park KW; Na HR
    J Alzheimers Dis; 2018; 63(3):1035-1044. PubMed ID: 29710726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sudden Discontinuation of Anti-dementia Drugs in Moderate and Severe Alzheimer's Disease in a Residency for Dependent Elderly People: a Longitudinal Descriptive Pilot Study].
    Peyro Saint-Paul L; Martin J; Gaillard C; Garnier A; Mosquet B; Guillamo JS; Parienti JJ
    Therapie; 2015; 70(4):313-9. PubMed ID: 25679184
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.